Related Experiment Video
Updated: Jul 17, 2025
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Metformin-suppressed platelet's function in vitro: Possible relation to delayed or failure of platelet-rich fibrin
Takashi Uematsu1, Hideo Masuki1, Masayuki Nakamura1
1Tokyo Plastic Dental Society, Kita-Ku, Tokyo, Japan.
Abstract:
Platelet-rich fibrin (PRF) is a popular autologous blood-derived biomaterial that is used in regenerative therapy. Owing to its simple preparation without additional factors, the PRF quality directly reflects the characteristics of individual blood samples. Antiplatelet or anticoagulant drugs can hamper the successful preparation of PRF. We recently observed similar phenomena in metformin-taking type-2 diabetics (T2DM). Thus, we hypothesized that metformin interferes with platelet function, thereby suppressing coagulation. For practical reasons, leukocyte- and platelet-rich plasma was prepared from healthy male donors (n = 9-15, age: 26-80 years) and treated with metformin (1-10 mM) for 24-72 h. Intrinsic and extrinsic coagulation activities were evaluated using prothrombin time (PT) and activated partial thromboplastin time (ATPP). Platelet adhesion and aggregation assays were performed using ADP stimulation. Among the parameters tested, APTT was the most sensitive and was significantly prolonged in the concentration range of 1-10 mM in a time- and concentration-dependent manner. Although obtained from healthy platelets and relatively higher concentrations of metformin, these findings suggest that metformin may induce further dysfunction of platelets to suppress intrinsic coagulation activity in T2DM patients, leading to failure of PRF preparation. This phenomenon may not have a severe impact on clinical diabetology or hematology. However, clinicians using PRF are recommended to be more sensitive to such information to avoid unexpected events in clinical settings.
Insights
Metformin may impair platelet function, potentially hindering platelet-rich fibrin (PRF) preparation in type-2 diabetics. This suggests clinicians should monitor patients on metformin for PRF treatment success.
Area of Science:
- Biomaterials Science
- Hematology
- Pharmacology
Background:
- Platelet-rich fibrin (PRF) is an autologous biomaterial vital for regenerative therapies.
- PRF preparation quality is sensitive to blood sample characteristics and medications.
- Metformin, a common type-2 diabetes drug, has been anecdotally linked to PRF preparation issues.
Purpose of the Study:
- To investigate the effect of metformin on platelet function and coagulation.
- To determine if metformin interferes with the preparation of platelet-rich fibrin (PRF).
- To assess the impact of metformin on intrinsic and extrinsic coagulation pathways.
Main Methods:
- Leukocyte- and platelet-rich plasma from healthy donors was treated with metformin (1-10 mM) for 24-72 hours.
- Coagulation activity was assessed using prothrombin time (PT) and activated partial thromboplastin time (APTT).
- Platelet adhesion and aggregation were evaluated following ADP stimulation.
Main Results:
- Activated partial thromboplastin time (APTT) was significantly prolonged by metformin in a time- and concentration-dependent manner (1-10 mM).
- Metformin demonstrated a dose-dependent inhibitory effect on intrinsic coagulation.
- Platelet function assays indicated potential interference with platelet activity.
Conclusions:
- Metformin may induce platelet dysfunction, suppressing intrinsic coagulation and potentially leading to PRF preparation failure in type-2 diabetic patients.
- Clinicians utilizing PRF should be aware of metformin's potential impact to prevent unexpected clinical outcomes.
- While not severely impacting diabetology or hematology, this interaction warrants clinical consideration for PRF procedures.
